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Acute myocardial infarction (AMI)complicated by cardiogenic shock (CS)
has an incidence of 7-10 % of patients despite
all the advances in reperfusion and
antithrombotic therapy. Mortality associated
with CS ranges between 45-80 %. The
commonest cause of CS is primary left
ventricular failure, the others being some of
the mechanical complications of AMI, namely
free wall rupture, papillary muscle rupture or a
ventricular septal defect. Studies that enrolled
large numbers of patients with AMI, like Gusto
I (SK vs tPA), showed that among the 41021
patients included, CS occurred in 7.2 % with a
30-day mortality of 55 %. Interestingly, the
mortality was significantly lower in those
patients with CS who 
underwent coronary revascularisation using
PTCA, and the benefit was even more evident
at the end of the first year of follow-up. In
another exhaustive analysis of the
characteristics of 55 000 patients with AMI
with ST-elevation (STEMI) randomized into
Gusto I and Gusto III the mortality of patients
in the latter was higher than the former (55 %
vs. 62 %, respectively). Remarkably, the
mortality of patients with CS treated outside
the US was higher, in both trials. In both these
trials the proportion of patients who underwent
revascularization along with implantation of an
intra-aortic balloon pump in the US was
higher, suggesting a beneficial role for these
two approaches in this clinical scenario. In a
report from California, CS occurred in 1.7 % of
63 964 patients with a mortality of 56 %. On
multivariate analysis, age greater than 60
years, previous MI, diabetes and female sex
were poor prognostic factors for survival, while
hypertension and revascularization were good
prognostic factors. Revascularization decreased
mortality by about 80 % (OR 0.2, p<0.0001).
Also in the NRMI, an analysis of about 3000
patients undergoing thrombolysis or PTCA in
STEMI, while the results did not confirm
superiority of PTCA over thrombolysis for
STEMI in patients with CS, in those who
underwent PTCA mortality was decreased
significantly. Although all this evidence
suggested the beneficial effect of these
strategies in CS, randomized clinical trials
providing conclusive evidence were lacking
until S(MASH) and SHOCK, trials led by P.
Urban and J. Hochman, respectively.
S(MASH), which tested the hypothesis that
revascularization improved survival, had to be
terminated prematurely due to poor enrolment
and in those randomized the hypothesis was
not confirmed at 30 days. SHOCK tested the
same hypothesis, with 302 patients and results
at 30 days and 6 months showed a survival
benefit for those revascularized in the cohort
that was less than 75 years of age. This benefit
was even more pronounced at one year, where
revascularisation showed a decrease in
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mortality (13.2 % less in those revascularised).
It is important to emphasize the difference in
the enrolment criteria of these two studies.
S(MASH) enrolled patients with a systolic
blood pressure (SBP) less than 90 mmHg
despite inotropic support whereas SHOCK
included patients with a SBP of less than 90
mm Hg for 30 minutes with or without
inotropic support. This in our opinion suggests
that the patients in S(MASH) were
hemodynamically more compromised than
those in SHOCK.
The current ACC/AHA guidelines for
primary PCI in transmural MI are as follows –
class I supported by level of evidence A – “ In
patients within 36 hours of an acute ST
elevation/Q-wave or new LBBB MI who
develop cardiogenic shock, are less than 75
years of age, and revascularization can be
performed within 18 hours of the onset of
shock, by individuals skilled in the procedure
(>75 PCI/year) and supported by experienced
personnel and appropriate laboratory
experience (>200 PCI/ year)’’.
However, despite all these advances these
patients still have high mortality. What
adjuvant therapy can be used to improve
survival in these patients? Although
controversial, these patients receive inotropic
support with amines. Although these
substances can increase coronary perfusion,
they can also increase oxygen consumption
and increase the release of inflammatory
cytokines which can decrease LV function. We
believe they are useful, although it is difficult
to be absolutely certain about this conviction.
The results of STOPAMI and ADMIRAL
provided convincing evidence for the benefit of
one glycoprotein IIb/IIIa inhibitor in primary
PCI during acute MI when a stent was placed
in the IRA. A potential beneficial role in the
subset of patients with cardiogenic shock has
not been established, however. There is some
evidence in PURSUIT for a role for these
agents in patients with cardiogenic shock. In
9449 patients in this study about 2.5 % had
shock and the mortality in this group of pa-
tients differed based on the use of eptifibatide
(58 % if it was used compared to 73 %, if not
used, p=0.03). Regarding distal protective
devices, the use of which has proved beneficial
in saphenous vein grafts by preventing distal
embolization, a role for these devices may be
envisaged in the setting of no-reflow, as this854
clinical situation can initiate and maintain
shock. However, even this role needs
confirmation.
Equally controversial is the role of intra-
aortic balloon pumps – and the SHOCK
Registry was particularly important in
demonstrating a beneficial effect on mortality
especially in the subgroup of patients in
conjunction with thrombolysis. Some
circulatory assist devices have been tested in
CS with promising results – the TANDEM
Heart device, which requires a transeptal
puncture allowing to rest the LV while
maintaining peripheral perfusion effectively.
The area of cardiogenic shock is one of the
most exciting areas in the field of acute
coronary syndromes where considerable
advances may be foreseen. Among
pharmacological agents, nitric oxide synthase
inhibitors may have an important role.
It is important to take home two
fundamental ideas in the management of these
patients. Those who present with AMI and CS
should undergo angiography and
revascularization as soon as possible and this
applies to those patients who also develop CS
in hospital. Despite all the advances it is
important to realize that this group of patients
often have various comorbid conditions and
therefore require intensive care of high quality
due to the frequent need for mechanical
ventilation and prolonged inotropic support.
The management of various clinical situations
that can often increase the mortality of these
patients while in intensive care should also be
the focus of physicians who care for these
patients.
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